Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI(encorafenib) capsules in combination with MEKTOVI(binimetinib)tablets... Read More

Thursday June 28, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Ron Squarer

Array BioPharma reports positive survival results for melanoma drugs

Array BioPharma reports positive survival results for melanoma drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) andFrance-based Pierre Fabreannounced results of a study of overall survival in patients with BRAF -mutant melanoma, indicating that treatment with... Read More

Wednesday February 7, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Victor Sandor

Array’s triplet drug combination found effective for colorectal cancer treatment

Array’s triplet drug combination found effective for colorectal cancer treatment

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet... Read More

Monday January 22, 2018 0 comments Tags: Boulder, Array BioPharma, binimetinib, encorafenib, cetuximab, Pierre Fabre

Array BioPharma announces FDA acceptance to review new melanoma drug applications

Array BioPharma announces FDA acceptance to review new melanoma drug applications

BOULDER -- Array BioPharma (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of... Read More

Wednesday September 13, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

BOULDER -- Array BioPharma (Nasdaq:ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of... Read More

Wednesday July 5, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib, encorafenib

Array BioPharma, Pierre Fabre announce positive results for cancer drug

Array BioPharma, Pierre Fabre announce positive results for cancer drug

BOULDER -- Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS ( Co mbined L GX818 U sed with M EK162 in B RAF... Read More

Monday September 26, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, Keith T. Flaherty, encorafenib, binimetinib, Frederic Duchecesne, COLUMBUS

Array BioPharma closes agreement with Pierre Fabre to commercialize cancer products

Array BioPharma closes agreement with Pierre Fabre to commercialize cancer products

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) today announced closing a definitive agreement with France-based Pierre Fabre following approval of the agreement by the European Commission on... Read More

Monday December 21, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, binimetinib, encorafenib

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) and France-based Pierre Fabre are collaborating to globally develop and commercialize Arrays late-stage novel oncology products, binimetinib and... Read More

Tuesday November 17, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, Ron Squarer, binimetinib, encorafenib